Generic Ryzumvi Availability
Last updated on Apr 10, 2025.
Ryzumvi is a brand name of phentolamine ophthalmic, approved by the FDA in the following formulation(s):
RYZUMVI (phentolamine mesylate - solution;ophthalmic)
-
Manufacturer: FAMYGEN LIFE SCI
Approval date: September 25, 2023
Strength(s): EQ 0.75% BASE [RLD]
Is there a generic version of Ryzumvi available?
No. There is currently no therapeutically equivalent version of Ryzumvi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ryzumvi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Patent 10,278,918
Issued: May 7, 2019
Inventor(s): Meyer Alan
Assignee(s): Ocuphire Pharma, Inc.The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
Patent expiration dates:
- January 31, 2034✓
- January 31, 2034
-
Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Patent 10,772,829
Issued: September 15, 2020
Inventor(s): Meyer Alan
Assignee(s): Ocuphire Pharma, Inc.The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
Patent expiration dates:
- January 31, 2034✓
- January 31, 2034
-
Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Patent 11,090,261
Issued: August 17, 2021
Inventor(s): Meyer; Alan
Assignee(s): Ocuphire Pharma, Inc. (Farmington Hills, MI)The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
Patent expiration dates:
- January 31, 2034✓
- January 31, 2034
-
Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
Patent 11,400,077
Issued: August 2, 2022
Inventor(s): Pitlick; William H. et al.
Assignee(s): Ocuphire Pharma, Inc. (West Bloomfield, MI)The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Patent expiration dates:
- October 25, 2039✓
- October 25, 2039
-
Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Patent 11,844,858
Issued: December 19, 2023
Inventor(s): Meyer; Alan R.
Assignee(s): Ocuphire Pharma, Inc. (Farmington Hills, MI)The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
Patent expiration dates:
- January 31, 2034✓
- January 31, 2034
-
Methods and compositions for treatment of mydriasis
Patent 12,201,615
Issued: January 21, 2025
Inventor(s): Sooch; Mina et al.
Assignee(s): Opus Genetics, Inc. (Farmington Hills, MI)The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Patent expiration dates:
- December 25, 2039✓
- December 25, 2039
-
Methods and compositions for treatment of mydriasis
Patent 12,201,616
Issued: January 21, 2025
Inventor(s): Sooch; Mina et al.
Assignee(s): Opus Genetics, Inc. (Farmington Hills, MI)The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Patent expiration dates:
- October 25, 2039✓
- October 25, 2039
-
Aqueous ophthalmic solutions of phentolamine and medical uses thereof
Patent 9,795,560
Issued: October 24, 2017
Inventor(s): Meyer Alan
Assignee(s): Ocularis Pharma, LLCThe invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
Patent expiration dates:
- January 31, 2034✓
- January 31, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 25, 2026 - NEW PRODUCT
More about Ryzumvi (phentolamine ophthalmic)
- Compare alternatives
- Drug images
- Dosage information
- FDA approval history
- Drug class: miscellaneous ophthalmic agents
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
